HPPI

Helsinn is a privately owned Swiss pharmaceutical group with a specialized focus on cancer care and supportive care products. The company operates an integrated business model that spans research and development, manufacturing, and commercialization of therapeutic agents designed to improve the quality of life for patients with cancer and chronic diseases. Helsinn's portfolio includes market-leading products for chemotherapy-induced nausea and vomiting (CINV) and cancer-related cachexia. Beyond its own pipeline, the company provides contract manufacturing services for highly potent active pharmaceutical ingredients (HPAPIs) through its specialized facilities. Helsinn maintains a global presence through a network of commercial partners and subsidiaries in key markets including the United States and China.